N-13 ammonia

Phase 3Small molecule

SStanford University

N-13 ammonia is one of 5 small molecule programs targeting CRC. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CRCRecruiting

CRCPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in CRC

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 2

2 2

Eloxatin

Teva

Phase 2

1 3

Erbitux

IImclone

Phase 2

2 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 2

1 5

N-13 ammonia

SStanford University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Post-ApprovalRecruiting

CRC

NCT03275584

Clinical

Trials by Indication[1]

Stress1 trial

Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress

Completed·MMayo Clinic·N/A·NCT01370265·12 enrolled

Cardiac1 trial

Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT

Completed·SStanford University··NCT03170817·15 enrolled

CRC1 trial

Safety of PET MPI Using the CRCHUM N-13 Ammonia

Recruiting·—·Phase 4·NCT03275584·20,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for N-13 ammonia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — N-13 ammonia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for N-13 ammonia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SStanford University

N-13 ammonia

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Stress1 trial

Cardiac1 trial

CRC1 trial

References

Drug Info

Quick Facts

Related News